Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Assets (2016 - 2025)

Historic Current Assets for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $698.4 million.

  • Ani Pharmaceuticals' Current Assets rose 3397.39% to $698.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $698.4 million, marking a year-over-year increase of 3397.39%. This contributed to the annual value of $527.7 million for FY2024, which is 151.36% up from last year.
  • Ani Pharmaceuticals' Current Assets amounted to $698.4 million in Q3 2025, which was up 3397.39% from $602.6 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Current Assets' 5-year high stood at $698.4 million during Q3 2025, with a 5-year trough of $182.8 million in Q1 2021.
  • Moreover, its 5-year median value for Current Assets was $459.3 million (2023), whereas its average is $420.5 million.
  • In the last 5 years, Ani Pharmaceuticals' Current Assets skyrocketed by 8892.27% in 2021 and then plummeted by 78.94% in 2025.
  • Ani Pharmaceuticals' Current Assets (Quarter) stood at $321.8 million in 2021, then rose by 6.99% to $344.3 million in 2022, then soared by 50.99% to $519.8 million in 2023, then increased by 1.51% to $527.7 million in 2024, then soared by 32.35% to $698.4 million in 2025.
  • Its Current Assets stands at $698.4 million for Q3 2025, versus $602.6 million for Q2 2025 and $536.3 million for Q1 2025.